Livingstone advises neoplas med’s series B financing round

Livingstone’s healthcare team in Düsseldorf has continued its advisory for neoplas med GmbH and its second funding round. Niterra (formerly NGK Spark Plug Co., LTD) expands its partnership with the medtech company through a growth investment in partnership with Pegasus Technology Ventures. The investment aims to support the internationalization of neoplas med from Greifswald, Germany and to advance the development of new products and applications of cold plasma technology.

In June 2022, Livingstone advised neoplas med GmbH in its initial financing round and was able to win the Japanese technology group NGK Spark Plug (operating as Niterra since April 2023) as a strategic partner. neoplas med has developed a therapy for the treatment of chronic and infected wounds in which cold plasma is applied without contact, under visual control, and nearly pain-free. The cold plasma from the kINPen® MED kills germs and pathogens and stimulates microcirculation as well as neovascularization and cell proliferation.

Niterra is a Japanese tech group specializing in spark plugs, sensor technology and technical ceramics since its inception. Its medical division develops respiratory, women’s health, homecare, and cold plasma technologies. With a balance sheet of $1+ billion and a $100 million corporate venture capital fund established in partnership with Pegasus Tech Ventures, they globally invest in cutting-edge technologies including medical devices.

“We have doubled our sales in 2022 and we thank our strategic partner Niterra for their trust and support in driving the internationalization and development of new distribution channels. We are proud of the strong result and pleased that Niterra will continue to extend its strategic commitment. This is another milestone in our efforts to further develop our ground-breaking jet plasma technology and make it available to as many people as possible worldwide,” says Ulrike Sailer, CEO neoplas med GmbH.

 “neoplas med technology and its recognition in the medical community appealed to us from the very beginning. Headed by Ulrike Sailer, the company has developed very well, and I am very excited about its further growth potential,” says Dirk Schapeler, President of Niterra Ventures Company.

Dr. Ralf Nowak, Partner at Livingstone in Düsseldorf comments: “We are very pleased to accompany neoplas med on its way from a start-up to a dynamic technology company. Niterra is an ideal partner for neoplas med, supporting the ongoing journey of internationalization and the diversification of the product base as well as the application areas.”